Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

Also called NCT02744339

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02744339
  • EudraCT 2014-003055-60
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02744339. Randomized; double masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2020-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Acronym
DYNAMIC
Condition
Hypertension, Pulmonary
Condition
Heart Failure With Normal Ejection Fraction
Intervention (Drug)
Riociguat
Intervention (Drug)
Placebo
Lead sponsor
Medical University of Vienna (class: other)

Record details

Record id
cardio:ct-nct02744339
Content hash
332b8ac6f3ac18cca7fcd144253755d8e53797bcf1d6f34b705057aec66f26b9